 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
211 News |  |
- Amiket (amitriptyline/ketamine) / Immune Pharma
[VIRTUAL] Isoniazid-associated Peripheral Neuropathy in a “Slow Acetylator”: Need for Pharmacogenomics in Tuberculosis treatment? () - Mar 18, 2021 - Abstract #AAN2021AAN_1865;
Prior knowledge of this patient’s genotype preceding and during therapy may have led to drug-level monitoring and prevention of her painful polyneuropathy. Others have demonstrated elevated risk of organ damage in “slow acetylator” NAT2 genotypes, including polyneuropathy, in other populations where tuberculosis is more common.
- | Amiket (amitriptyline/ketamine) / Immune Pharma
Trial completion, Trial primary completion date: ATTRACT-CPN: Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients (clinicaltrials.gov) - Jun 10, 2015
P3, N=462, Completed, Sponsor: Gary Morrow
Others have demonstrated elevated risk of organ damage in “slow acetylator” NAT2 genotypes, including polyneuropathy, in other populations where tuberculosis is more common. Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Sep 2013